Bacterial and Viral Specimen Collection

Global Bacterial and Viral Specimen Collection Market to Reach US$41.3 Billion by 2030

The global market for Bacterial and Viral Specimen Collection estimated at US$19.3 Billion in the year 2024, is expected to reach US$41.3 Billion by 2030, growing at a CAGR of 13.6% over the analysis period 2024-2030. Bacterial Specimen Collection, one of the segments analyzed in the report, is expected to record a 15.0% CAGR and reach US$30.9 Billion by the end of the analysis period. Growth in the Viral Specimen Collection segment is estimated at 9.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.2 Billion While China is Forecast to Grow at 18.4% CAGR

The Bacterial and Viral Specimen Collection market in the U.S. is estimated at US$5.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$8.9 Billion by the year 2030 trailing a CAGR of 18.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.8% and 12.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.8% CAGR.

Global Bacterial and Viral Specimen Collection Market – Key Trends & Drivers Summarized

Why Is Bacterial and Viral Specimen Collection Critical to Diagnostics, Disease Surveillance, and Global Health Security?
Bacterial and viral specimen collection plays a foundational role in clinical diagnostics, epidemiological surveillance, infection control, and public health response. Accurate detection of infectious agents begins with the reliable collection, transport, and preservation of biological samples such as nasopharyngeal swabs, blood, saliva, stool, sputum, and tissue biopsies. These specimens are essential for identifying pathogens, monitoring antimicrobial resistance (AMR), conducting genomic sequencing, and supporting pandemic preparedness initiatives.

In a post-COVID-19 landscape, where global attention to viral threats has intensified, specimen collection systems are under renewed scrutiny for their ability to preserve sample integrity, prevent contamination, and ensure compatibility with high-throughput molecular testing platforms. As healthcare systems scale up testing for a range of bacterial and viral illnesses—including tuberculosis, influenza, HIV, RSV, and emerging zoonotic threats—robust specimen collection infrastructure has become a critical enabler of diagnostic accuracy, therapeutic decisions, and health system responsiveness.

How Are Transport Media, Automation Compatibility, and Cold Chain Innovations Advancing Specimen Integrity and Workflow Efficiency?
Technological innovation in specimen collection is focused on enhancing sample stability, biosafety, and operational scalability. Universal transport media (UTM), viral transport media (VTM), and bacterial-specific collection kits are being optimized with antimicrobial agents, cryopreservatives, and pH buffers to ensure pathogen viability and nucleic acid integrity during transit. Pre-filled, sterile collection tubes with leak-resistant caps, tamper-proof labels, and barcoding systems are streamlining traceability and minimizing handling errors.

Swab technologies have advanced with synthetic flocked tips, break-off shafts, and ergonomically designed handles for consistent sample uptake and patient comfort. Collection devices are increasingly engineered for compatibility with automated lab systems, supporting rapid processing and minimizing technician exposure. Cold chain advancements—such as phase-change materials and portable passive cooling units—are improving field-to-lab transport of temperature-sensitive viral specimens in remote or resource-limited settings. These developments are critical to supporting decentralized testing, global surveillance networks, and real-time outbreak response.

Where Is Market Demand Expanding and Which End-User Segments Are Driving Growth?
Market demand for bacterial and viral specimen collection solutions is expanding globally, with strong momentum in regions strengthening infectious disease surveillance, including North America, Europe, China, India, and parts of Africa and Southeast Asia. Government-funded public health programs, pandemic readiness investments, and expanded diagnostic capabilities at the primary care level are fueling demand in both developed and developing healthcare systems.

Hospitals, diagnostic laboratories, public health agencies, and point-of-care (PoC) testing centers represent the largest user base, particularly for respiratory and sexually transmitted infections (STIs). Additionally, pharmaceutical and biotech companies are significant consumers of specimen collection kits for clinical trials and vaccine R&D. In epidemiology, NGOs and global health agencies rely on validated collection systems for field sample collection in disease-endemic regions, making specimen kits critical for global AMR monitoring, biosurveillance, and outbreak containment.

What Is Fueling the Global Growth of the Bacterial and Viral Specimen Collection Market?
The global market for bacterial and viral specimen collection is being driven by heightened infectious disease awareness, growth in diagnostic testing, and the integration of molecular diagnostics into routine care. The COVID-19 pandemic catalyzed significant infrastructure upgrades, including stockpiling of collection kits, expanded laboratory networks, and digitized supply chain systems that are now being leveraged for broader testing mandates. Ongoing threats from antimicrobial resistance, zoonotic spillovers, and seasonal epidemics have ensured that specimen collection remains a strategic investment focus for both governments and private healthcare providers.

Regulatory harmonization, investment in decentralized diagnostics, and the rise of at-home and self-collection kits are expanding access to specimen collection tools beyond institutional settings. Strategic collaborations between diagnostics manufacturers, public health organizations, and logistics providers are enhancing end-to-end sample chain integrity. As precision medicine and pathogen genomics become central to disease control and prevention, a critical question defines the future of this sector: Can the global specimen collection ecosystem adapt to rising diagnostic complexity and demand—while ensuring quality, scalability, and access in a rapidly evolving infectious disease landscape?

SCOPE OF STUDY:

The report analyzes the Bacterial and Viral Specimen Collection market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Bacterial Specimen Collection, Viral Specimen Collection); Application (Diagnostics, Research); End-User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institution, Other End-Users)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Becton, Dickinson and Company
• BioMérieux SA
• COPAN Diagnostics Inc.
• DiaSorin S.p.A.
• GenMark Diagnostics, Inc.
• Hardy Diagnostics
• HiMedia Laboratories Pvt. Ltd.
• Hologic, Inc.
• Longhorn Vaccines and Diagnostics, LLC
• Medical Wire & Equipment Co. Ltd.
• Nest Scientific Biotechnology
• Pretium Packaging, LLC
• Puritan Medical Products
• Quidel Corporation
• Roche Diagnostics
• Spectrum Solutions, LLC
• Thermo Fisher Scientific Inc.
• Titan Biotech Ltd.
• Trinity Biotech plc
• VIRCELL S.L.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.